June 21, 2024


You are Your Only Limit

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Fascination Down 59.9% in Could

2 min read

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Ranking) saw a substantial drop in small desire in Might. As of May possibly 15th, there was short desire totalling 54,500 shares, a decrease of 59.9% from the April 30th total of 136,000 shares. Based on an normal day-to-day quantity of 3,570,000 shares, the times-to-include ratio is currently . times. Presently, .8% of the shares of the stock are sold brief.

LIXT traded down $.01 throughout buying and selling on Friday, reaching $.76. The company had a trading quantity of 2,706 shares, when compared to its ordinary quantity of 3,650,878. The business’s fifty day going normal price is $1.20 and its 200 working day relocating typical rate is $1.46. Lixte Biotechnology has a 12 month low of $.72 and a 12 thirty day period substantial of $4.95.

Several institutional buyers have just lately modified their holdings of the stock. BlackRock Inc. elevated its stake in Lixte Biotechnology by 191.9% in the 3rd quarter. BlackRock Inc. now owns 13,425 shares of the company’s stock really worth $28,000 immediately after acquiring an extra 8,826 shares all through the very last quarter. Morgan Stanley acquired a new situation in Lixte Biotechnology for the duration of the 1st quarter valued at about $69,000. EP Prosperity Advisors LLC purchased a new stake in Lixte Biotechnology in the 1st quarter well worth close to $31,000. Last but not least, Geode Money Administration LLC ordered a new stake in Lixte Biotechnology in the course of the 3rd quarter valued at around $78,000. 8.82% of the stock is currently owned by institutional traders.

Lixte Biotechnology Enterprise Profile (Get Ranking)

Lixte Biotechnology Holdings, Inc operates as a drug discovery enterprise that works by using biomarker technological know-how to determine enzyme targets relevant with critical prevalent disorders and designs novel compounds to attack those people targets. The corporation primarily focuses on inhibitors of protein phosphatases that are employed on your own and in mixture with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two key classes of compounds at various levels of pre-medical and clinical development.

Featured Stories

Get Information & Ratings for Lixte Biotechnology Every day – Enter your e mail handle below to get a concise day by day summary of the newest information and analysts’ ratings for Lixte Biotechnology and associated corporations with MarketBeat.com’s Cost-free day-to-day email e-newsletter.

bionpa.com All rights reserved. | Newsphere by AF themes.